Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > TIGIT class of checkpoint inhibitors fails with Keytruda

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 09, 2023 4:42pm

117 Views

Post# 35489267

RE:RE:TIGIT class of checkpoint inhibitors fails with Keytruda

From these developments one can see that Big Pharma is having significant difficulty in finding novel cancer therapies, at the same time that Big Pharma is faced with a looming patent cliff. We also see that Roche has bet heavily on the TIGIT class of checkpoint inhibitors.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing